NL-OMON34076已完成2 期
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Pharmacodynamic and -kinetic study of 3 transdermal EE and GSD formulations
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy female volunteers
- •age 18 - 35 years (smoker not older than 30 years, inclusive)
- •ovulatory pre-treatment cycle
排除标准
- •- Contraindications for use of combined (estrogen/gestodene) contraceptive (e.g. history of venous or arterial thromboembolic disease)
- •- Regular intake of medication other than Oral Contraception
- •- Clinically relevant findings (blood pressure, physical and gynecological examination, laboratory examination)
研究者
相似试验
进行中（未招募）
不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulationsPrevention of PregnancyMedDRA version: 12.1Level: LLTClassification code 10060346Term: Transdermal contraceptionEUCTR2010-021255-81-NLBayer HealthCare AG174
进行中（未招募）
不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulationsEUCTR2010-021255-81-DEBayer HealthCare AG174
进行中（未招募）
不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetics of transdermal EE and GSDThe trial will be performed in healthy female volunteers. The intended indication is femal contraception.EUCTR2009-009177-10-DEBayer HealthCare AG
进行中（未招募）
1 期
Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized PatientsEUCTR2020-002037-15-ESCristina Avendaño Sola200
进行中（未招募）
1 期
Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age - LCS Pearl Index StudyContraceptionMedDRA version: 9.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2007-000420-40-FRBayer Schering Pharma Oy